← All stocks

Rezolute, Inc.

RZLT Net buying

CIK 0001509261 #3185 in the set updated 21 Sep 2026

Bought (12 mo)

$235.70K

out of their own pocket, the only kind of buying there is

Sold (12 mo)

$0.00

$0.00 on a plan · $0.00 straight out of an exercise

Sold at will

$0.00

0 of 0 sales

Net

+$235.70K

+$235.70K against sales at will

By person

10 insiders · 9 transactions

2.8×

Nevan Charles Elam holds only 2.8 times base salary in stock. $1.73M of shares against $610.83K in salary for 2025.

Salary from the company's own proxy. The shares are what Nevan Charles Elam last reported holding, valued at $2.85, the price Common Shares was last bought or sold at on the open market here, on 30 Mar 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Evans Daron

CFO

$108.08K (4)

—

+$108.08K

418,400

0.4345%

$1.19M

+269.1%

Elam Nevan C

CEO

$50.88K (1)

—

+$50.88K

605,497

0.6288%

$1.73M

+7,646%

ROBERTS BRIAN KENNETH

Chief Medical Officer

$47.60K (1)

—

+$47.60K

293,851

0.3052%

$837.48K

+466.7%

Karnawat Sunil Ratilal

Chief Commercial Officer

$19.60K (2)

—

+$19.60K

79,173

0.0822%

$225.64K

+541.6%

Hogenhuis Wladimir

Director

$9.55K (1)

—

+$9.55K

119,675

0.1243%

$341.07K

+219.1%

Kim Young-Jin

Director

—

8,594,336

8.93%

$24.49M

+17.6%

KREHER NERISSA

Director

—

58,576

0.0608%

$166.94K

—

Labrucherie Gil M

Director

—

55,500

0.0576%

$158.18K

—

FAUCHET PHILIPPE

Director

—

55,500

0.0576%

$158.18K

—

Harris Erik

Director

—

21,000

0.0218%

$59.85K

—

Individual transactions

Nothing of that kind in this period.

What was left out

Form 4 filings counted 23

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 0

Sales straight out of an exercise 0

Sales at will 0

Transactions with no price 0

Shares from compensation/vesting 771,890

History held since 13 Jan 2017